AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15522707 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sleep apnoea syndrome (SAS)
Number of subjects: 0
Study 10899450 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise recovery of phosphocreatine in Friedreich ataxia patients after ischemic exercise.
Number of subjects: 0
Study 10899450 — intervention group
Group type: EXPERIMENTAL
Intervention: Time constants of recovery of phosphocreatine.
Number of subjects: 0
Study 9200172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 10 micrograms/kg
Number of subjects: 10
Study 9200172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 20 micrograms/kg
Number of subjects: 10
Study 9200172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 40 micrograms/kg
Number of subjects: 10
Study 9200172 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study 8440860 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity progressive resistance training of the hip and knee extensors 3 days per week
Number of subjects: 0
Study 8440860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplementation with a 360-kcal high carbohydrate, low fat liquid supplement every day
Number of subjects: 0
Study 8440860 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high intensity progressive resistance training and multi-nutrient supplementation
Number of subjects: 0
Study 8440860 — intervention group
Group type: COMPARATOR
Intervention: Liquid placebo every day (control group)
Number of subjects: 0
Study 8440860 — intervention group
Group type: COMPARATOR
Intervention: Leisure activities (non-exercising groups)
Number of subjects: 0
Study 3758471 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing nicomethanol hydrofluoride
Number of subjects: 76
Study 3758471 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste containing potassium nitrate and sodium monofluorophosphate
Number of subjects: 76
Study 31884902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stepping intervention
Number of subjects: 110
Study 31884902 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 30144938 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month PA coaching intervention (Walk On!)
Number of subjects: 2707
Study 30144938 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2707
Study 27460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg
Number of subjects: 120
Study 27460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.75 µg/kg
Number of subjects: 120
Study 27460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg
Number of subjects: 120
Study 27460746 — intervention group
Group type: COMPARATOR
Intervention: Propofol only (control group)
Number of subjects: 120
Study 25027174 — intervention group
Group type: EXPERIMENTAL
Intervention: Completely anonymous survey condition
Number of subjects: 324
Study 25027174 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 incentive
Number of subjects: 324
Study 25027174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate privacy condition
Number of subjects: 324
Study 22718030 — intervention group
Group type: COMPARATOR
Intervention: Whey protein 0 g (Control)
Number of subjects: 327
Study 22718030 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein 10 g
Number of subjects: 327
Study 22718030 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein 20 g
Number of subjects: 327
Study 22718030 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein 30 g
Number of subjects: 327
Study 21188316 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary program intervention
Number of subjects: 37
Study 21188316 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 37
Study 18986069 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparency interpretation possible with unrestrained presentation times
Number of subjects: 0
Study 18986069 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparency interpretation inhibited by occluding local junctions
Number of subjects: 0
Study 18986069 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparency interpretation possible with short presentation times
Number of subjects: 0
Study 18986069 — intervention group
Group type: EXPERIMENTAL
Intervention: Unambiguous stimulus displays without specific attentional instructions
Number of subjects: 0
Study 15936361 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK cage containing a biphasic calcium phosphate ceramic (Triosite)
Number of subjects: 100
Study 15936361 — intervention group
Group type: COMPARATOR
Intervention: PEEK cage containing an autogenous iliac bone graft
Number of subjects: 100
Study 12950521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antiplatelet therapy
Number of subjects: 0
Study 12950521 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation therapy with warfarin
Number of subjects: 0
Study 10394282 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilizing exercise (n = 15)
Number of subjects: 27
Study 10394282 — intervention group
Group type: COMPARATOR
Intervention: Mobilizing exercise (n = 12)
Number of subjects: 27
Study 8744104 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms/day for 6 months)
Number of subjects: 11
Study 8744104 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 11
Study 1906161 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin administered every 6 hours
Number of subjects: 34
Study 1906161 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin administered every 8 hours
Number of subjects: 34
Study 6504709 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomers (‐2.5/+80 mg)
Number of subjects: 37
Study 6504709 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomers (‐5/+80 mg)
Number of subjects: 37
Study 6504709 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacrinone enantiomers (‐10/+80 mg)
Number of subjects: 37
Study 6504709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30020447 — intervention group
Group type: COMPARATOR
Intervention: 3 days of oral azithromycin (A3)
Number of subjects: 216
Study 30020447 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 days of oral doxycycline (D3)
Number of subjects: 216
Study 30020447 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of oral doxycycline (D7)
Number of subjects: 216
Study 30043524 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 2.0 mg
Number of subjects: 1524
Study 30043524 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment regimens
Number of subjects: 1524
Study 26807718 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-oxidative therapy (pravastatin 40 mg/d and vitamin E 300 mg/d)
Number of subjects: 62
Study 26807718 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no anti-oxidants)
Number of subjects: 62
Study 24972936 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume low pressure nasal saline + fluticasone propionate (3 weeks)
Number of subjects: 91
Study 24972936 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (antibiotherapy + nasal decongestant) (2 weeks)
Number of subjects: 91
Study 24972936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 22170366 — intervention group
Group type: EXPERIMENTAL
Intervention: CSB++ (75 kcal/kg/day)
Number of subjects: 2612
Study 22170366 — intervention group
Group type: COMPARATOR
Intervention: Soy RUSF
Number of subjects: 2612
Study 22170366 — intervention group
Group type: COMPARATOR
Intervention: Soy/whey RUSF
Number of subjects: 2612
Study 20682669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 4.5 g/night
Number of subjects: 151
Study 20682669 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (SXB) 6 g/night
Number of subjects: 151
Study 20682669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 17435611 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC) (100 mg elemental iron)
Number of subjects: 100
Study 17435611 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (FS) (120 mg elemental iron)
Number of subjects: 100
Study 17435611 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC)
Number of subjects: 100
Study 17435611 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate (FS)
Number of subjects: 100
Study 17435611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of treatment
Number of subjects: 100
Study 15590762 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (loading dose of 4 mg/kg IV over 30 min, followed by 0.4 mg/kg/min for at least 6 hours, then 350 mg orally three times daily for 4 days)
Number of subjects: 0
Study 15590762 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered in control arm)
Number of subjects: 0
Study 14565810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas (tolazamide, glyburide, glipizide GITS, glimepiride) with insulin
Number of subjects: 40
Study 14565810 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride with insulin
Number of subjects: 40
Study 14565810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas with insulin
Number of subjects: 40
Study 14565810 — intervention group
Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 40
Study 10395630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg per day
Number of subjects: 341
Study 10395630 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty followed by usual care
Number of subjects: 341
Study 10395630 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 341
Study 8908821 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day for one month, then 200 mg/day)
Number of subjects: 76
Study 8908821 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 76
Study 1909085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (2 L daily of 3.5% crystalline amino acids in 5% dextrose) plus standard therapy
Number of subjects: 39
Study 1909085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone (20 mg orally four times a day) plus standard therapy
Number of subjects: 39
Study 1909085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxandrolone and nutritional supplementation plus standard therapy
Number of subjects: 39
Study 1909085 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (abstinence, balanced diet, multivitamins)
Number of subjects: 39
Study 7060255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase, 500 IU/kg i.v., every 6 hours for 42 hours
Number of subjects: 48
Study 7060255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 7060255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase, 500 IU/kg i.v., every 6 hours for 42 hours (among 21 patients treated within 6 hours of onset)
Number of subjects: 48
Study 7060255 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase and Placebo
Number of subjects: 48
Study 31981558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (approximately 20 mg per kg of bodyweight)
Number of subjects: 40375
Study 31981558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40375
Study 30296721 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Summer Youth Employment Program (SYEP)
Number of subjects: 0
Study 30296721 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28501886 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed visible and ultraviolet (UVA and UVB) light source application (mUV/VIS)
Number of subjects: 50
Study 28501886 — intervention group
Group type: COMPARATOR
Intervention: Visible light alone (placebo)
Number of subjects: 50
Study 25377762 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant crying (10 minutes)
Number of subjects: 98
Study 25377762 — intervention group
Group type: COMPARATOR
Intervention: Infant cooing (10 minutes)
Number of subjects: 98
Study 23661689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 5249
Study 23661689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5249
Study 23661689 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 5249
Study 23661689 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 5249
Study 20553131 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium healing abutments
Number of subjects: 16
Study 20553131 — intervention group
Group type: COMPARATOR
Intervention: Polymer healing abutments
Number of subjects: 16
Study 19481808 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof phakic angle-supported intraocular lens (IOL) implantation
Number of subjects: 190
Study 17926822 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg/day for treatment-naive patients, 1 mg/day for patients with lamivudine failure)
Number of subjects: 0
Study 17926822 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 0
Study 17926822 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir
Number of subjects: 0
Study 15545858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanometric findings (type B tympanogram)
Number of subjects: 90
Study 15545858 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanocentesis (TAP)
Number of subjects: 90
Study 15545858 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoscopy and tympanometry
Number of subjects: 90
Study 11782044 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical imputation strategies (last observation carried forward, mean and regression based methods)
Number of subjects: 0
Study 11782044 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric strategies (rank and dichotomization based methods)
Number of subjects: 0
Study 11782044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean of the other group or counted as treatment failures after dichotomization of the endpoint
Number of subjects: 0
Study 11782044 — intervention group
Group type: EXPERIMENTAL
Intervention: No adequate recommendations can be given
Number of subjects: 0
Study 9289526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone (1-2 g once a day)
Number of subjects: 274
Study 9289526 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac (100 mg two times each day)
Number of subjects: 274
Study 9289526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 274
Study 9289526 — intervention group
Group type: COMPARATOR
Intervention: Aceclofenac
Number of subjects: 274
Study 8295814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin oral suspension (7.5 mg/kg; maximum, 500 mg)
Number of subjects: 379
Study 8295814 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor oral suspension (20 mg/kg; maximum, 500 mg)
Number of subjects: 379
Study 8295814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 379
Study 8295814 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 379
Study 8295814 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin and cefaclor
Number of subjects: 379
Study 3771808 — intervention group
Group type: COMPARATOR
Intervention: 10-day placebo washout
Number of subjects: 45
Study 31654501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept and focal/grid laser photocoagulation
Number of subjects: 22
Study 28679200 — intervention group
Group type: EXPERIMENTAL
Intervention: INTELLiVENT‐ASV®
Number of subjects: 60
Study 28679200 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation modes
Number of subjects: 60
Study 27623561 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Ultrasound (TCD) rescreening
Number of subjects: 3840
Study 27623561 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP Protocol (combination of risk stratification with TCD and selective chronic red cell transfusion)
Number of subjects: 3840
Study 24966408 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural banana odor
Number of subjects: 61
Study 24966408 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial banana odor
Number of subjects: 61
Study 24966408 — intervention group
Group type: COMPARATOR
Intervention: Water (no odor)
Number of subjects: 61
Study 24966408 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sniffing of banana odors
Number of subjects: 61
Study 22383124 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-peer teaching
Number of subjects: 558
Study 20525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day, n = 24)
Number of subjects: 72
Study 20525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day, n = 24)
Number of subjects: 72
Study 20525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Ezetimibe and Simvastatin (n = 24)
Number of subjects: 72
Study 20525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 72
Study 20525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Ezetimibe + Simvastatin)
Number of subjects: 72
Study 20525999 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 72
Study 18210156 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in IGFBP2 and IGFBP5
Number of subjects: 0
Study 18210156 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of 34 single nucleotide polymorphisms (SNPs)
Number of subjects: 0
Study 16356293 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Recurrence Prevention (DRP) program (n=112)
Number of subjects: 267
Study 16356293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of the DRP program with psychiatric consultation (PC+DRP, n=39)
Number of subjects: 267
Study 16356293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination with brief cognitive behavior therapy (CBT+DRP, n=44)
Number of subjects: 267
Study 16356293 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU, n=72)
Number of subjects: 267
Study 12727966 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d)
Number of subjects: 60
Study 12727966 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d) with N(G)-monomethyl-L-arginine infusion
Number of subjects: 60
Study 10783546 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized version of the Job Descriptive Index (JDI) scales
Number of subjects: 2286
Study 10783546 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil version of the Job Descriptive Index (JDI) scales
Number of subjects: 2286
Study 8778585 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant hirudin
Number of subjects: 12142
Study 8778585 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 12142
Study 1317910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 32
Study 1317910 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 32
Study 1317910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Chlorthalidone + Clonidine)
Number of subjects: 32
Study 3937815 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi‐Euglucon N 1.75 mg
Number of subjects: 8
Study 3937815 — intervention group
Group type: EXPERIMENTAL
Intervention: Daonil N 1.75 mg
Number of subjects: 8
Study 3937815 — intervention group
Group type: COMPARATOR
Intervention: Semi‐Euglucon 2.5 mg
Number of subjects: 8
Study 3937815 — intervention group
Group type: COMPARATOR
Intervention: Daonil 2.5 mg
Number of subjects: 8
Study 3937815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HB 420 preparations
Number of subjects: 8
Study 3937815 — intervention group
Group type: COMPARATOR
Intervention: Both HB 419 preparations
Number of subjects: 8
Study 3937815 — intervention group
Group type: EXPERIMENTAL
Intervention: HB 420 preparations
Number of subjects: 8
Study 3937815 — intervention group
Group type: COMPARATOR
Intervention: Other HB 419 preparation
Number of subjects: 8
Study 31219698 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Mind-Set Single-Session Intervention (GM-SSI)
Number of subjects: 222
Study 31219698 — intervention group
Group type: COMPARATOR
Intervention: Computer-based active control program (teaching healthy sexual behaviors)
Number of subjects: 222
Study 28814418 — intervention group
Group type: EXPERIMENTAL
Intervention: MatchedFlicker programme
Number of subjects: 100
Study 28814418 — intervention group
Group type: COMPARATOR
Intervention: Stereo viewer
Number of subjects: 100
Study 28814418 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate image pairs
Number of subjects: 100
Study 27293194 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib (50 mg BID) in combination with rituximab
Number of subjects: 37
Study 27293194 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxtalisib (50 mg BID) in combination with rituximab+bendamustine
Number of subjects: 37
Study 25922233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant group (5-HT3-receptor antagonist + dexamethasone + aprepitant or fosaprepitant)
Number of subjects: 413
Study 25922233 — intervention group
Group type: COMPARATOR
Intervention: Control group (5-HT3-receptor antagonist + dexamethasone)
Number of subjects: 413
Study 25922233 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant group
Number of subjects: 413
Study 25922233 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 413
Study 23619375 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 144
Study 23619375 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 144
Study 23619375 — intervention group
Group type: COMPARATOR
Intervention: Usual care-reduced measurement (UC-RM)
Number of subjects: 144
Study 20886400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy during oral double-balloon enteroscopy (DBE)
Number of subjects: 156